Menopause and joint pain: what is true, what is false
Joint pain and stiffness are among the most common complaints of menopause, and they are largely underestimated. What truly comes from the drop in estrogen, what comes from osteoarthritis, what hormone therapy actually changes (in the Women's Health Initiative randomized trial, 76.3% of women on estrogen reported joint pain after one year versus 79.2% on placebo, about three percentage points that the authors themselves call modest) and what glucosamine, chondroitin and turmeric are worth. In French with English subtitles.
Watch on YouTube (full description and references) →
Read the written and sourced version of this topic →
What you will understand
Joint pain is among the most common complaints of perimenopause, and probably among those least taken seriously. The usual answers are two equally discouraging phrases: "it is your age" or "it is in your head". This video refuses both, without tipping into the opposite excess, which would be to blame everything on menopause.
What the data show, first. A longitudinal cohort published in the journal Pain in 2024, which followed 609 women across the stages of menopause, observes that the frequency and intensity of muscle and joint pain increase as the transition advances, with late perimenopause standing out as a turning point. It is an observational study: it establishes a concomitance, not a causality. And it must immediately be set against its counterpoint, the large American SWAN cohort, which followed more than 3,000 women for sixteen years and whose authors titled their article "It is not just menopause". Pain there appears as a block with fatigue, sleep problems and hot flashes, and these symptom profiles already existed before menopause.
The video then examines the "musculoskeletal syndrome of menopause", a term proposed in 2024 in the journal Climacteric by a team led by orthopedic surgeon Vonda Wright. It puts a fitting word on a real experience, and its success is understandable. But we must be precise about its status: it comes from a narrative review (the weakest level of evidence), it has no validated diagnostic criteria, and no learned society has adopted it. The figure of "more than 70% of women" that you read everywhere is an estimate by the authors, not the result of a prevalence study.
On the role of estrogen, the strongest argument comes from elsewhere: aromatase inhibitors, prescribed after hormone-dependent breast cancer, deliberately collapse estrogen levels, and a meta-analysis of 21 studies covering more than 13,000 women finds that about 46% of them develop arthralgia. It is a form of natural experiment, but a brutal, artificial hormonal fall, in women often treated with chemotherapy: this figure does not transpose to natural menopause. Conversely, a review published in Osteoarthritis and Cartilage recalls that the differences between the knees of girls and boys are visible from childhood and "are not explained solely by sex hormones".
Then comes the question of hormone therapy, treated without complacency. The best available data is a randomized placebo-controlled trial, the Women's Health Initiative, on 10,739 menopausal women. After one year, 76.3% of women on estrogen reported joint pain, versus 79.2% on placebo. The difference is real and holds up to the third year, but it represents about three percentage points, and the authors themselves use the word "modest". Worth noting, and it is rarely said: joint swelling was slightly more frequent on estrogen. No imaging, no cartilage was measured: nothing allows the claim that hormone therapy treats osteoarthritis.
The last part is the most useful day to day: what works, to what extent, and what does not work. Then the signals that should lead to a consultation, because not all joint pain after 45 is menopause, and in inflammatory diseases, an early diagnosis changes the prognosis.
The key points to remember
- Musculoskeletal pain increases across the stages of menopause, with late perimenopause as a turning point (cohort, Pain 2024, PMID 38787639). An observed association, not a cause-and-effect relationship.
- It almost never comes alone: SWAN shows that it forms a block with fatigue, sleep and hot flashes, and that these profiles already existed before menopause (PMID 29326841).
- The "musculoskeletal syndrome of menopause" is a term proposed in 2024 in a narrative review. It is not a validated diagnosis: no criteria, and no learned society has adopted it (PMID 39077777).
- About 46% of women on aromatase inhibitors develop arthralgia (meta-analysis, PMID 28204994), a strong argument for the role of estrogen, but a figure that does not transpose to natural menopause.
- Hormone therapy: 76.3% joint pain on estrogen versus 79.2% on placebo in the WHI randomized trial. A real effect but described as "modest" by the authors, and joint swelling was slightly more frequent on treatment (PMID 30358728).
- Hormone therapy does not treat osteoarthritis: no structural endpoint was measured in this study, and joint relief is not one of its indications.
- Exercise is the best documented intervention (Cochrane review, 139 randomized trials, more than 12,000 participants), with low to moderate certainty of evidence and a benefit whose clinical importance the authors themselves say remains uncertain (PMID 39625083).
- Glucosamine and chondroitin: "either ineffective, or with weak effects of arguably no clinical importance", according to the best available synthesis (PMID 29018060).
- Signals that deserve medical advice: prolonged morning stiffness, a swollen or warm joint, shoulder and pelvic girdle pain after 50, fever, night sweats, unexplained weight loss, a shoulder losing its mobility.
Frequently asked questions
Does menopause hormone therapy relieve joint pain?
A little, and much less than people say. In the estrogen-only arm of the Women's Health Initiative (a randomized placebo-controlled trial on 10,739 hysterectomized menopausal women), 76.3% of treated women reported joint pain after one year, versus 79.2% on placebo. The difference is statistically real and holds up to the third year, but it represents about three percentage points: the authors themselves describe it as "modest". The flip side must also be mentioned: joint swelling was slightly more frequent on estrogen (42.1% versus 39.7%). Joint relief is not an indication for hormone therapy, and it remains a personalized medical decision to make with the professional who knows your file.
Is the "musculoskeletal syndrome of menopause" a real diagnosis?
Not to date. The term was proposed in 2024 in the journal Climacteric by a team led by orthopedic surgeon Vonda Wright, who explicitly writes "we introduce a new term". It is a narrative review, that is, an argued synthesis (the weakest level of evidence in the scientific hierarchy) and not a prevalence study. This syndrome is not recognized by any medical classification, has no validated diagnostic criteria, and no learned society has adopted it. The figure of "more than 70% of women" relayed on social media is an estimate by the authors. The term remains useful because it names a real experience, but do not expect a doctor to recognize it as a diagnosis.
Do collagen, turmeric, glucosamine or chondroitin really help?
The best available synthesis is a meta-analysis of 69 studies covering 20 supplements, published in the British Journal of Sports Medicine. On glucosamine and chondroitin (the best sellers), the conclusion of the authors is unambiguous: they were "either ineffective, or with weak effects of arguably no clinical importance". Turmeric, curcumin and hydrolyzed collagen do show short-term effects, sometimes of substantial size, but the authors judge the overall quality of the evidence "very low", and no supplement keeps a clinically important effect in the medium or long term. Also worth noting: these data concern osteoarthritis, not specifically the arthralgia of menopause, for which no quality data exist.
Which exercise should you choose when you are in pain?
The one you will do regularly, but if you are looking for a starting point, endurance exercise has the best track record. A 2024 Cochrane review, gathering 139 randomized trials and more than 12,000 participants on knee osteoarthritis, shows that exercise improves pain, function and quality of life: about 13 points better on a 0 to 100 scale compared with doing nothing. The authors remain cautious: low to moderate certainty of evidence, benefit demonstrated in the short term, clinical importance uncertain. A network meta-analysis published in the BMJ in 2025, on 217 trials, puts aerobic exercise first for pain, with strength training and mixed programs standing out mostly on function. Exercise remains, by far, the best documented, cheapest and least risky intervention.
When should you consult rather than attribute your pain to menopause?
Some signals deserve medical advice: stiffness on waking that lasts well beyond a few minutes, a joint that swells or becomes warm, shoulder and pelvic girdle pain after 50 accompanied by stiffness, general signs such as fever, night sweats or unexplained weight loss, a shoulder that progressively loses its mobility, or pain that wakes you at night and worsens despite movement. None of these signs means something serious is going on: most pain at this age has mundane explanations. But in inflammatory diseases such as rheumatoid arthritis or polymyalgia rheumatica, rheumatologists speak of a "window of opportunity": diagnosed early, they are controlled much better. This page is educational and does not replace a consultation.
Does this pain really come from menopause?
Only in part, and honesty demands nuance. A cohort published in the journal Pain in 2024, which followed 609 women across the stages of menopause, observes that the frequency and intensity of pain increase as the transition advances. But the large American SWAN cohort, which followed more than 3,000 women for sixteen years, titled its article "It is not just menopause": this pain forms a block with fatigue and sleep, and these profiles already existed before.
Why talk about aromatase inhibitors?
Because they constitute a form of natural experiment. These treatments, prescribed after hormone-dependent breast cancer, deliberately collapse estrogen levels, and a meta-analysis of 21 studies covering more than 13,000 women finds that about 46% of them develop arthralgia. It is a strong argument for the role of estrogen, but it is a brutal, artificial fall: this figure does not transpose to natural menopause.
Can hormone therapy treat osteoarthritis?
No, and it is a common confusion. In the Women's Health Initiative randomized trial, no imaging was performed and no cartilage parameter was measured: only the pain reported by participants was collected. The difference observed on joint pain there was real but described as modest by the authors. Nothing therefore allows the claim of an effect on the structure of the joint.